Dynamic albumin values as clinical surrogate for COVID-19 therapeutics
J Investig Med
.
2021 Aug;69(6):1260.
doi: 10.1136/jim-2021-001895.
Epub 2021 May 28.
Authors
Johanna S van Zyl
1
2
,
Joost Felius
1
2
,
Amit Alam
2
3
4
,
Shelley A Hall
2
3
4
,
Aayla K Jamil
1
2
,
Cedric W Spak
5
6
,
Robert L Gottlieb
7
2
3
4
8
Affiliations
1
Baylor Scott & White Research Institute, Baylor Scott & White Health, Dallas, Texas, USA.
2
Texas A&M University Health Science Center, Dallas, Texas, USA.
3
Center for Advanced Heart and Lung Disease, Baylor University Medical Center, Dallas, Texas, USA.
4
Division of Cardiology, Baylor University Medical Center, Dallas, TX, USA.
5
Division of Infectious Disease, Baylor University Medical Center, Dallas, Texas, USA.
6
Texas Centers for Infectious Disease Associates, Dallas, Texas, USA.
7
Baylor Scott & White Research Institute, Baylor Scott & White Health, Dallas, Texas, USA
[email protected]
.
8
Division of Precision Medicine, Baylor University Medical Center, Dallas, TX, USA.
PMID:
34050000
DOI:
10.1136/jim-2021-001895
No abstract available
Keywords:
COVID-19; inflammation; serum albumin.
Publication types
Letter
Comment
MeSH terms
Acute-Phase Proteins
COVID-19*
Humans
Retrospective Studies
SARS-CoV-2
Serum Albumin*
Substances
Acute-Phase Proteins
Serum Albumin